Prototyping OSA: A New Framework for Predicting Cardiovascular Outcomes and CPAP Benefit

Five OSA prototypes were identified in 2,676 SAVE trial participants, with Prototype 1 showing the highest ESS, FRS, and MACE rate and Prototype 5 the lowest.

• Why it matters: OSA is linked to major adverse cardiac events, yet CPAP has not reduced MACE in randomized trials, suggesting unmeasured subgroup heterogeneity.
• What they did: In a secondary analysis of SAVE, multi-domain Gaussian mixture models selected five prototypes using Bayesian information criterion and C-index, then Cox models estimated MACE risk and a causal survival forest estimated prototype-specific CPAP effects.
• The result: Prototype 5 was predicted to benefit from CPAP (p<0.05), while Prototypes 1, 3, and 4 showed no benefit or possible harm, supporting prototype-guided targeting after external validation.

AI summary of the abstract · may contain errors · not medical advice · read the paper.